Quantifying the proportion of French citizens who have developed SARS-CoV-2 antibodies and documenting the effects of the epidemic on their living conditions appear as key factors in preparing the most appropriate deconfinement and prevention strategies, in enabling the early detection of any resurgence of the epidemic and, over the longer term, in monitoring the efficacy of the measures taken.
Driven by Inserm and the Directorate for Research, Studies, Assessment and Statistics (DREES) of France’s Ministry of Solidarity and Health, in conjunction with their partners (National Institute of Statistics and Economic Studies [INSEE], Public Health Agency, National Center for Scientific Research [CNRS], National Institute for Demographic Studies [INED], Université Paris-Saclay), EpiCOV is a large-scale epidemiological study based on a major statistical survey. It is proposing global and scientifically reliable mapping of population immune status and dynamics across the French territory through the collection of biological samples paired with questionnaires.
The aims of EpiCOV are twofold: to provide precise mapping of the population’s immune status, health, living conditions and the social inequalities relating to these three parameters, and to monitor the dynamics of the epidemic over the short, medium, and long term. The exceptionally rapid deployment of a large-scale epidemic surveillance cohort that is statistically representative at local level will in particular provide data used in modelling the epidemic.
With this project, it will be possible to elucidate the spatial, temporal, sociodemographic and familial aspects of the epidemic and of the confinement measures. It aims to describe the frequency of COVID-19 symptoms, supply data for models of population immunity evolution, provide estimations of the frequency of exposure to the virus, including the asymptomatic forms of transmission, and evaluate changes in the health, wellbeing and behaviors of people living in France. Intended to be both precise and representative of the entire French population, it includes geographically and sociodemographically defined subgroups. All French departments (including certain overseas departments and regions [DROM]) will be included in the survey.
The first wave of data collection will take place from April 30 to May 24, with a second wave to come in June. This operation may be repeated regularly to monitor the dynamic of the epidemic and the evolution of the country’s health and social conditions, across all territories, age groups and major social groups.
Initial findings based on responses to the questionnaires should be available on a national scale at the end of May.
The first results of the biological samples will be provided as early as possible from the end of May, depending on the availability of qualified serological tests currently under development and the capacity of the test platforms.
A local authorities-researchers liaison committee will be established in order to present the study, discuss the initial findings and their consequences, and disseminate information concerning additional studies initiated on the territories.
Bacillary dysentery caused by the intestinal bacteria Shigella is a major health problem in tropical regions and developing countries. Complications from this infection lead to several hundred thousand deaths a year, primarily among infants. Researchers from Inserm and the Institut Pasteur have ...
A research team from Inserm, Lille University, Lille University Hospital, CNRS, and the Institut Pasteur of Lille, as part of the Lille Immunity and Infection Center, is developing a new vaccine against whooping cough. En utilisant la bactérie entière mais génétiquement modifiée ...